As UDI regulations continue to evolve worldwide, ensuring compliance with the latest updates is essential. Stay ahead of regulatory changes and streamline your UDI implementation with expert guidance. Contact us to navigate the complexities of UDI compliance efficiently.

• Changes to the Global Medical Device Nomenclature (GMDN) field
• Enhanced user experience features, and responsibilities for maintaining accurate device identifier (DI) records.

This comprehensive framework ensures that device labelers have the necessary resources to navigate and comply with GUDID requirements effectively.

Overview of Key Changes

Updates to GMDN Code Requirements and Removal of FDA Preferred Term (PT) Codes

Since April 2019, the GMDN Agency has allowed access to GMDN code without requiring a paid membership. As a result, the option to use FDA PT Codes is no longer necessary, and the FDA intends to remove these codes from the GUDID.

References to FDA PT codes are being removed from the guidance. Going forward, GUDID users must use GMDN codes.

New Section on Maintaining GMDN Codes in DI Records

Labelers are responsible for maintaining accurate and up-to-date DI record information throughout the device’s Total Product Lifecycle (TPLC).

For GMDN Members: Notifications will be provided when terms are modified or become obsolete.

For Non-Members: Labelers are responsible for monitoring their GMDN terms periodically or when required by validation rules.

If a GMDN Term becomes obsolete, the labeler or LDE user must update the GMDN Term to ensure successful validation when modifying any other DI record attribute.

Once a DI record is published in the GUDID with an active GMDN Term, that assignment remains unchanged unless updated by the labeler or LDE user. The GUDID does not automatically update GMDN terms.

Updates to GMDN information must be submitted within 10 business days of any change

Enhancements to User Experience

Database improvements aim to streamline the user experience through better validation rules and user interface enhancements. Feedback will continue to shape system updates, with periodic revisions to the guidance reflecting these changes.

Specific Considerations for HCT/P Labelers

Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) are required to assign and label each HCT/P with a distinct identification code. This code must enable manufacturers to relate the HCT/P to the donor and all associated records. The distinct identification code may include:

• Donation identification number
• Serial number
• Lot number
• A combination of these production identifiers

HCT/P labelers regulated as medical devices should ensure they select the appropriate type of production identifier that matches the device label in the GUDID.

Conclusion

The updated guidance serves as a critical resource for device labelers, outlining the importance of maintaining accurate and up-to-date DI records throughout a device’s lifecycle. By transitioning fully to GMDN codes, eliminating outdated FDA PT Codes, and implementing enhanced database features, the GUDID ensures a streamlined and compliant framework for device identification. These updates support better data accuracy, user experience, and regulatory adherence.

What Is Unique Device Identification (UDI)?

The unique device identification system is a globally recognized framework that enables precise tracking of medical devices. Each medical device is assigned a unique device identification number, which serves as a “digital fingerprint” for the product. The UDI includes critical information about the device’s version or model and its production details, making it easy to identify, track, and recall, if necessary.

The FDA’s UDI rule applies to most classes of medical devices, and manufacturers must meet these requirements to ensure their products are safely and effectively managed in the healthcare environment.

Why FDA UDI Compliance Is Essential for Medical Devices

FDA UDI compliance serves several vital purposes, including:

• Enhanced Patient Safety: By uniquely identifying devices, UDI enables faster response times for recalls or safety notifications.
• Improved Traceability: With each device uniquely identified, manufacturers and healthcare providers can easily track devices throughout their lifecycle.
• Regulatory Adherence: FDA mandates UDI for many medical devices, meaning that compliance is necessary to legally market products in the U.S.

Non-compliance can lead to penalties, restricted market access, or delayed regulatory approvals. Consequently, meeting UDI requirements is not only a legal necessity but also a step toward enhancing operational efficiency and brand trust in the healthcare industry.

Key FDA Requirements for UDI Compliance

FDA UDI compliance involves a series of guidelines that manufacturers need to adhere to. Let’s look at the primary requirements:

1. UDI Structure: Device Identifier (DI) and Production Identifier (PI)

A UDI comprises two primary components:

• Device Identifier (DI): This part of the UDI is specific to the device model or version and remains consistent for each device of that type.
• Production Identifier (PI): This segment includes variable information, such as the device’s serial number, lot or batch number, expiration date, and manufacturing date.

The combination of DI and PI ensures that each device can be uniquely identified and traced, making it easier to manage product recalls and post-market surveillance.

2. Labeling and Marking Requirements

The FDA requires that the UDI be prominently displayed on the device’s label and packaging in both human-readable and machine-readable formats, such as barcodes or QR codes. For certain devices, like those intended for re-use or that must be sterilized, the UDI must be directly marked on the device itself.

The labeling requirements ensure that the UDI is accessible and readable by both healthcare providers and automated systems, enabling quick identification in real-world settings. Compliance with labeling requirements is essential, as improper labeling can lead to fines and delays in device approval.

3. Submission to the Global Unique Device Identification Database (GUDID)

To meet FDA requirements, manufacturers must submit UDI data to the Global Unique Device Identification Database (GUDID). This public database stores UDI information, allowing healthcare providers, patients, and the FDA to access accurate data about medical devices.

Manufacturers need to register their devices and maintain updated records in GUDID, which includes key device details like:

• Manufacturer name and contact information
• Device version or model
• Regulatory classifications and intended use

By ensuring UDI data is available in the GUDID, the FDA can monitor device performance, manage recalls more effectively, and conduct market surveillance.

4. Class-Specific Compliance Timelines

FDA UDI compliance is implemented across different classes of medical devices, with each class having specific timelines. Devices are typically categorized into three primary classes based on risk:

• Class I (Low Risk): Devices like bandages or surgical instruments.
• Class II (Moderate Risk): Devices such as catheters and infusion pumps.
• Class III (High Risk): High-risk devices like pacemakers or heart valves.

While most Class II and Class III devices are already required to comply with FDA UDI rules, Class I devices have been given more time. Understanding these timelines helps manufacturers prioritize compliance according to the FDA’s phased approach.

Steps for Medical Device Manufacturers to Achieve UDI Compliance

To achieve FDA UDI compliance, manufacturers must follow a systematic approach:

1. Establish a UDI Implementation Strategy

Creating a UDI implementation strategy is the first step. This involves determining which devices require UDI, understanding labeling and marking needs, and identifying any special requirements for direct marking. Having a clear strategy ensures that all compliance aspects are met without significant delays.

2. Invest in Labeling and Data Management Systems

Manufacturers should invest in labeling systems that can handle both human- and machine-readable UDI formats. High-quality barcode printing and scanning systems are essential to ensure UDI accuracy. Additionally, data management systems are crucial to keep records updated in the GUDID, track device distribution, and simplify recall processes.

3. Integrate UDI Compliance with Quality Management Systems (QMS)

FDA regulations require medical device manufacturers to implement and maintain a Quality Management System (QMS). Integrating UDI requirements within the QMS framework enables seamless compliance, as it combines all aspects of device production, quality control, and regulatory adherence under a single system. The QMS can serve as a foundation for managing UDI-related data and tracking the lifecycle of each device.

4. Conduct Regular Audits and Training

Ensuring UDI compliance requires ongoing audits and training for staff involved in manufacturing, labeling, and quality control. Audits can identify potential compliance issues early on, while training ensures that employees understand FDA UDI requirements and know how to implement them correctly.

The Broader Impact of FDA UDI Compliance on the Medical Device Industry

The FDA’s UDI system has broad-reaching impacts across the healthcare industry, bringing a range of benefits and challenges:

1. Enhanced Patient Safety and Device Reliability

With UDI, healthcare providers can quickly identify devices, access accurate usage information, and address any recalls or adverse events more efficiently. This transparency enhances patient safety and supports more reliable device usage in healthcare settings.

2. Simplified Device Recalls and Incident Reporting

FDA UDI compliance enables more efficient recall processes, allowing manufacturers to quickly retrieve affected devices by their unique identifiers. Incident reporting also becomes faster and more accurate, as healthcare providers can report specific devices involved in adverse events.

3. Increased Cost and Time Investments for Manufacturers

Achieving UDI compliance can be costly for manufacturers, particularly in terms of labeling technology, data management, and training. While the upfront costs can be substantial, these investments lead to better compliance management and potential long-term savings in recall-related expenses.

4. Improved Data Analytics and Market Surveillance

With UDI data accessible through the GUDID, healthcare providers, regulatory bodies, and manufacturers gain valuable insights into device performance, usage trends, and market demand. This data improves the industry’s ability to detect emerging issues, adapt to market changes, and enhance product development.

Overcoming Common Challenges in UDI Compliance

The path to UDI compliance comes with challenges, such as:

• Complex Regulatory Landscape: Navigating UDI requirements alongside other global regulatory standards can be challenging, especially for international manufacturers.
• Technology Integration: Implementing new labeling systems, database management, and quality control systems requires investment and can disrupt existing workflows.
• Data Accuracy: Ensuring that UDI data is correctly formatted and regularly updated in the GUDID demands ongoing attention and resources.

Manufacturers can overcome these challenges by collaborating with regulatory consultants, investing in the right technology solutions, and conducting regular audits to ensure continuous compliance.

Conclusion

FDA UDI compliance is a cornerstone of modern medical device manufacturing, enhancing device traceability, safety, and quality across the healthcare industry. By adhering to UDI requirements—such as proper labeling, GUDID submission, and class-based compliance timelines—manufacturers not only fulfill regulatory obligations but also improve patient safety, streamline recalls, and gain valuable market insights. While UDI implementation can

What Is Unique Device Identification (UDI)?

The unique device identification system is a framework for labeling medical devices with a specific identifier, the UDI, which enables accurate tracking and data collection throughout the device’s lifecycle. A UDI consists of two parts:

1. Device Identifier (DI): Identifies the specific version or model of the device.
2. Production Identifier (PI): Contains variable information related to production, such as lot number, expiration date, and serial number.

This identifier, displayed on device labels in human- and machine-readable forms, allows regulatory bodies, manufacturers, and healthcare providers to track medical devices for improved patient safety, easier recalls, and more efficient inventory management.

Why Global UDI Implementation Matters

Given the international reach of many medical device companies, understanding the nuances of UDI requirements across different regions is essential. Non-compliance with UDI regulations in any given market can restrict a manufacturer’s ability to sell products in that area, which can have significant financial and operational repercussions. With each region implementing its UDI regulations in unique ways, manufacturers must adopt a tailored approach to meet compliance in each market.

UDI Implementation in Key Regions

The global adoption of the UDI system is led by major regulatory bodies, each with its own requirements and compliance timelines. Let’s explore the key differences in UDI regulations across regions.

1. United States: FDA UDI Requirements

The Food and Drug Administration (FDA) was the first major regulatory body to mandate the UDI system, introducing requirements in 2013 for medical devices sold in the United States. The FDA’s UDI rule applies to most devices and emphasizes patient safety through accurate device tracking. Key requirements include:

• Labeling Requirements: All UDI labels must contain both human-readable and machine-readable information, typically as a barcode.
• Global Unique Device Identification Database (GUDID): Manufacturers must submit UDI information to the FDA’s GUDID database, which stores critical device information accessible by healthcare providers and the public.
• Class-Based Compliance Timelines: The FDA rolled out UDI requirements in phases based on device risk class, with high-risk (Class III) devices required to comply first, followed by moderate-risk (Class II) and low-risk (Class I) devices.

The FDA’s phased approach emphasizes patient safety and helps manufacturers adapt their production and labeling systems. Non-compliance can result in penalties, market access restrictions, or delays in FDA approval.

2. European Union: MDR and EUDAMED Database

The European Union’s approach to UDI is outlined in the Medical Device Regulation (MDR), which replaced the previous Medical Device Directive (MDD) and introduced strict UDI requirements for devices marketed in the EU. The EU’s UDI framework shares some similarities with the FDA’s but has unique elements:

• Labeling and Data Submission Requirements: Like the FDA, the EU requires UDI labels to be human- and machine-readable. However, the EU mandates that UDI data be submitted to the European Database on Medical Devices (EUDAMED).
• Direct Marking Requirements: For certain reusable devices that must undergo sterilization, the EU requires direct marking of the UDI on the device itself.
• Device Classifications and Timelines: The EU’s MDR categorizes devices by risk, with higher-risk devices required to comply first. Although implementation has been delayed, compliance deadlines for MDR UDI requirements are approaching quickly, especially for Class I and II devices.

The EUDAMED database is central to the EU’s approach, allowing regulatory bodies across the EU to access accurate, updated device data. EUDAMED is not yet fully operational, but manufacturers must prepare for its eventual activation to ensure compliance.

3. Japan: UDI under PMDA Guidance

Japan, known for its rigorous medical device regulations, follows UDI requirements set by the Pharmaceuticals and Medical Devices Agency (PMDA). Japan’s UDI system, while similar in purpose to those in the U.S. and EU, has distinct features:

• Local Language Requirements: All UDI information must be displayed in Japanese, ensuring that healthcare providers can accurately read and interpret the labels.
• Japan Medical Device Nomenclature (JMDN): Japan mandates that devices include a JMDN code, a unique identifier specific to the Japanese regulatory framework, alongside the UDI.
• No Centralized Database Requirement: Unlike the FDA’s GUDID or the EU’s EUDAMED, Japan does not currently require submission of UDI data to a centralized database.

Manufacturers aiming to enter the Japanese market must prepare device labeling in Japanese and adapt to the local nomenclature requirements for successful UDI compliance.

4. China: NMPA UDI Regulations

China’s National Medical Products Administration (NMPA) has established its UDI system to improve device tracking and safety. China’s approach closely mirrors the FDA’s but has unique aspects tailored to the local market:

• China UDI Database: The NMPA requires that device information be submitted to a Chinese UDI database for regulatory oversight and tracking.
• Device Labeling in Chinese: All UDI information must be presented in Chinese, following NMPA guidelines to ensure local healthcare providers can read and verify device information.
• Phased Implementation: Similar to the FDA, China’s UDI requirements are phased in according to device risk class, prioritizing higher-risk devices for early compliance.

For manufacturers, navigating China’s regulatory landscape involves understanding local language requirements and ensuring compliance with the NMPA’s phased UDI timelines.

5. Other Regions: Australia, Brazil, and Canada

Several other countries have also begun implementing UDI frameworks, each with its own requirements:

• Australia: Australia’s Therapeutic Goods Administration (TGA) has been working to align its UDI requirements with international standards, though full implementation is still in progress.
• Brazil: The Brazilian Health Regulatory Agency (ANVISA) has signaled interest in UDI requirements, likely influenced by other major markets, though Brazil’s UDI system remains in development.
• Canada: Health Canada has been considering UDI implementation, looking to align its standards with those of the FDA and EU to facilitate market access and enhance patient safety.

As UDI requirements become standardized across these regions, global manufacturers must stay updated on changing regulations to avoid compliance issues and market entry delays.

Key Differences in Global UDI Requirements

To summarize, here are the primary differences in UDI requirements across regions:

1. Labeling Language and Format
   • U.S. and EU requirements are similar, using human- and machine-readable formats, while Japan and China mandate labels in local languages.
2. Centralized Databases
   • The U.S. (GUDID) and EU (EUDAMED) require UDI data submission to centralized databases. Japan and China have varying database requirements, with Japan not mandating a database submission.
3. Direct Marking Requirements
   • Direct marking on devices is required by the EU for reusable and sterilizable devices, while U.S. requirements may vary depending on device class and reusability.
4. Implementation Timelines by Device Class
   • Phased timelines for high-, moderate-, and low-risk devices vary across regions, requiring manufacturers to tailor compliance plans for each market.

Challenges and Solutions for Global UDI Compliance

For manufacturers, implementing UDI across multiple regions presents several challenges:

• Resource-Intensive Labeling and Translation Needs: Different language and labeling requirements necessitate significant investment in translation and labeling infrastructure.
• Varied Database Submissions: With each region’s unique database requirements, managing UDI data submissions can be complex and time-consuming.
• Ongoing Regulatory Updates: UDI regulations are evolving, and staying updated on new standards is essential for maintaining compliance.

To address these challenges, companies can:

• Invest in centralized data management systems that can be customized for regional requirements.
• Work with regulatory consultants to navigate UDI nuances across different markets.
• Use automated labeling and translation solutions to streamline UDI data preparation and ensure regulatory compliance.

Conclusion

The global implementation of unique device identification varies significantly across regions, with each regulatory body enforcing its own requirements and timelines. For medical device manufacturers, understanding and adhering to these regional UDI regulations is critical to ensure market access, enhance patient safety, and support device traceability. By developing tailored strategies for each market and investing in advanced data management systems, manufacturers can successfully navigate the complexities of global UDI compliance. Staying ahead in this dynamic regulatory landscape not only helps companies maintain compliance but also builds a reputation for quality, safety, and reliability in healthcare markets worldwide.

An UDI is a distinct numeric or alphanumeric code used to identify medical devices throughout healthcare supply chains. These codes are generated by product owners based on globally accepted standards for device identification.

The UDI code consists of two standard elements, which are:

• Device Identifier (DI): DI identifies the labeler and the model or version of a device. The DI is a required component and considered to be the static portion of the UDI, meaning that it is the same for all instances of the product model or version.
• Production Identifier (PI): PI identifies one or more variable characteristics, such as manufactured date, expiration date, lot number, or serial number. The PI is considered to be the dynamic portion of the UDI, meaning that the PI value changes according to the production controls.

The DI is always first and is followed by the PI if it has a value.

Unique Device Identifier (UDI) = Device Identifier (DI) + Production Identifier (PI)

There are different Issuing Agencies/ Entities for issuing an UDI for a medical device they are:

GS1: Global Standards 1 (GS1) are a nonprofit standards agency, GS1 sets international standards for supply chains, electronic data exchange, healthcare, and more. GTIN (Global Trade Item Number) and UPC (Universal Product Code) are GS1 standards, both are numeric only codes. GS1 provides a “GS1 Company Prefix” to a subscribing organization and reserves a range of “Item Reference” numbers for the organization to assign to their product portfolio. GS1 charges an initial fee and a lower annual renewal fee for the subscription. GS1 is used by the majority of medical device manufacturers.

HIBCC: Health Industry Business Communications Council (HIBCC) is a nonprofit organization focused on setting standards for the healthcare industry. The HIBC (Health Industry Bar Code) standard is managed by HIBCC and is an alphanumeric code. HIBCC provides a Labeler Identification Code (LIC) to an organization after paying a one-time subscription fee. The organization creates and assigns Product/Catalog Numbers (PCN) to their product portfolio without an additional charge.

ICCBBA: International Council for Commonality in Blood Banking Automation (ICCBBA) is a non-governmental organization. ICCBBA focuses exclusively on standards for medical products of human origin, such as blood products, tissues, and organs for transplant. It manages the ISBT 128 standard used in more than 75 countries. Only a few niche medical devices are identified using the ICCBBA standard.

Issuing Agency standards typically define a device identifier to encode a company, a product model, a package level, and a check character used to verify the accuracy of the code. 

UDI codes are included on the product and package labels and, in some cases, printed directly on the device itself. Regulations require the UDI be presented in both Automatic Identification and Data Capture (AIDC) and Human Readable Interpretation (HRI) formats.

The AIDC format is a one- or two-dimensional barcode. This format allows the product to be identified quickly and accurately by using barcode readers and scanner technologies. The HRI text format refers to easily readable text that allows the product to be identified by humans without the use of any scanning or barcode reader technology.

In the case of reused and reprocessed devices, such as a surgical scalpel, the UDI must be directly marked on the product, as the product packaging is discarded. There are different direct marking technologies such as laser etching, to mark the product for the life of the product.

Once the UDI is issued, the data must be securely stored in the manufacturer’s repository and submitted to the respective health authority’s Unique Device Identification Database (UDID).

In general, regulations require product UDI data to be reported to the UDID before the medical device is placed on the market. The UDI Device Identifier and numerous other data attributes need to be collected and submitted to the UDID.

An increasing number of health authorities are implementing UDI requirements to improve patient safety and the patient experience. Accurate, comprehensive product information gleaned from UDIDs is essential to ensure the correct and safe use of devices by all users, including patients, caregivers, healthcare providers, hospitals, and industry.

The primary goal of a UDI system is to ensure proper adverse event reporting among medical devices. UDI increases the accuracy of product traceability and enables medical device manufacturers, regulatory bodies, and other analysts to discover trends earlier and respond quicker in the event patient safety is at risk due to a certain device issue.

In order to effectively streamline UDI labeling and submissions for your medical devices, it is essential to have a thorough understanding of the entire process of development, validation, design, and submission of requirements. DDi offers a single Unique Device Identification (UDI) solution that meets compliance requirements across all countries.